BioCentury | Jun 29, 2018
Company News

Bio-Techne acquiring Exosome Diagnostics for $250M

...Diagnostics Inc., Waltham, Mass. Bio-Techne Corp. (NASDAQ:TECH), Minneapolis, Minn. Business: Diagnostic, Cancer Jaime De Leon ExoDx Prostate(IntelliScore), Prostate cancer liquid biopsy test (exo106) Bio-Techne...
BioCentury | Jun 26, 2018
Company News

Bio-Techne acquiring Exosome Diagnostics for $250M

...earnings targets. The parties expect the deal to close in July or early August. Exosome's ExoDx Prostate(IntelliScore)...
...cancer prior to biopsy. Bio-Techne was off $1.22 to $157.03 on Tuesday. Jaime De Leon ExoDx Prostate(IntelliScore), Prostate cancer liquid biopsy test (exo106) Bio-Techne...
BioCentury | May 26, 2017
Emerging Company Profile

Bypassing biopsies

Nanostics Inc. is analyzing biomarkers on tumor-derived vesicles in blood to increase the accuracy of routine prostate cancer screening, and provide a readout of a tumor's aggressiveness. When used with routine PSA screening, the company’s...
BioCentury | May 18, 2015
Clinical News

Prostate cancer liquid biopsy test: Clinical trial data

...men presenting for an initial prostate biopsy showed that the EXO106 score produced by Exosome’s prostate cancer liquid biopsy test...
...of prostate-specific antigen ( KLK3 ; PSA) levels, age, race and family history. Additionally, the EXO106...
...score (EXO106 Score) Indication: Detect high-grade prostate cancer Endpoint: Area under the curve (AUC) for EXO106...
BioCentury | Mar 30, 2015
Clinical News

Prostate cancer liquid biopsy test: Clinical trial data

...KLK3 ; PSA) levels of 2-10 ng/mL showed that the EXO106 score produced by Exosome’s prostate cancer liquid biopsy test...
...test in 1,064 patients are expected in mid-2015. Exosome Diagnostics Inc. , Cambridge, Mass. Product: Prostate cancer liquid biopsy test...
...analyzes the expression of 3 biomarkers utilizing exosomal RNA to determine a predictive risk score (EXO106...
BioCentury | Mar 17, 2014
Finance

Tuned up for cash flow

...more reproducible than tests requiring painful and invasive tissue extractions. Exosome's lead in vitro diagnostic, EXO106...
...multi-center study program involving more than 1,000 patient samples to assess the diagnostic performance of EXO106...
...specifics, as Exosome will submit the data for publication and presentation this year. He said EXO106...
BioCentury | Mar 12, 2014
Financial News

Exosome Diagnostics raises $27 million in series B

...cell lung cancer (NSCLC) and other malignancies. This year, Exosome also plans to launch its EXO106...
...reduce unnecessary biopsies in patients with elevated levels of prostate-specific antigen ( KLK3 ; PSA). EXO106...
Items per page:
1 - 7 of 7